Sector News

Monsanto bid may mean Bayer will cut pharma R&D spending

June 1, 2016
Chemical Value Chain

The proposed $62bn merger with agrochemical firm Monsanto would jeopardise Bayer’s pharmaceutical business, according to a BMI Research analyst.

> Read the full article on the in-Pharma Technologist website

By Dan Stanton

Source: in-Pharma Technologist

comments closed

Related News

September 22, 2023

ExxonMobil announces startup of $2-billion chemicals expansion in Baytown

Chemical Value Chain

ExxonMobil Corp. (Spring, Tex.) announced the startup of two new chemical production units at its Baytown, Texas, manufacturing facility. The $2 billion expansion is part of ExxonMobil’s long-term growth plans to deliver higher-value products from its U.S. Gulf Coast refining and chemical facilities.

September 22, 2023

Ineos acquires Eramet Titanium & Iron for €230 Million

Chemical Value Chain

Ineos Enterprises has announced the acquisition of Eramet Titanium & Iron (ETI) from Eramet for €230 million ($245 million). The deal was completed on Sept. 21 and takes immediate effect, following the satisfaction of regulatory approvals.

September 22, 2023

Arxada appoints Sanjeev Rastogi as CEO

Chemical Value Chain

Arxada has appointed Sanjeev Rastogi as Chief Executive Officer (CEO), effective immediately. He succeeds Marc Doyle who led Arxada since its foundation and will join the company’s board of directors as a non-executive member.

How can we help you?

We're easy to reach